Therefore, therapeutic strategies that target the Fas-FasL axis may be of benefit for patients with obesity who are also at risk of developing metabolic disease-related complications such as CVD and Type 2 diabetes mellitus. The gene discussed is FAS; the disease is obesity due to melanocortin 4 receptor deficiency.